AstraZeneca's Brilique Cleared In NICE's Initial Appraisal
The U.K.'s cost regulator, NICE, clears AstraZeneca's antiplatelet drug ticagrelor for use in the National Health Service in a preliminary assessment.
The U.K.'s cost regulator, NICE, clears AstraZeneca's antiplatelet drug ticagrelor for use in the National Health Service in a preliminary assessment.